Literature DB >> 8727919

Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole.

H Sanati1, S A Messer, M Pfaller, M Witt, R Larsen, A Espinel-Ingroff, M Ghannoum.   

Abstract

We have developed a microdilution method for measuring the susceptibility of Cryptococcus neoformans to fluconazole. The present study evaluated the interlaboratory agreement of the results for the microdilution method obtained at three different sites and compared this method with the National Committee for Clinical Laboratory Standards M27-P reference method. Excellent interlaboratory agreement among the results obtained at the three sites was achieved with this method (83 and 96% agreement within 1 and 2 log2 dilutions, respectively). An overall agreement of 90% between the microdilution method and the M27-P method was observed, demonstrating the comparability of the two methods. However, there are inherent problems with the M27-P method in relation to measuring C. neoformans susceptibility, including suboptimal growth of the organism in RPMI 1640, a longer incubation period, and a narrow range of MICs. On the basis of these data, the microdilution method tested in this study is recommended for inclusion in the National Committee for Laboratory Standards method for testing the antifungal susceptibility of C. neoformans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8727919      PMCID: PMC228998          DOI: 10.1128/jcm.34.5.1280-1282.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

1.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

2.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

Authors:  M S Saag; W G Powderly; G A Cloud; P Robinson; M H Grieco; P K Sharkey; S E Thompson; A M Sugar; C U Tuazon; J F Fisher
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

3.  Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans.

Authors:  M A Pfaller; C Grant; V Morthland; J Rhine-Chalberg
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

4.  Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome.

Authors:  S L Chuck; M A Sande
Journal:  N Engl J Med       Date:  1989-09-21       Impact factor: 91.245

5.  Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients.

Authors:  J J Stern; B J Hartman; P Sharkey; V Rowland; K E Squires; H W Murray; J R Graybill
Journal:  Am J Med       Date:  1988-10       Impact factor: 4.965

6.  Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.

Authors:  R A Larsen; S A Bozzette; B E Jones; D Haghighat; M A Leal; D Forthal; M Bauer; J G Tilles; J A McCutchan; J M Leedom
Journal:  Clin Infect Dis       Date:  1994-10       Impact factor: 9.079

7.  Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing.

Authors:  M D Witt; R J Lewis; R A Larsen; E N Milefchik; M A Leal; R H Haubrich; J A Richie; J E Edwards; M A Ghannoum
Journal:  Clin Infect Dis       Date:  1996-02       Impact factor: 9.079

8.  Susceptibility testing of Cryptococcus neoformans: a microdilution technique.

Authors:  M A Ghannoum; A S Ibrahim; Y Fu; M C Shafiq; J E Edwards; R S Criddle
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

9.  Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends.

Authors:  R M Selik; E T Starcher; J W Curran
Journal:  AIDS       Date:  1987-09       Impact factor: 4.177

10.  Multicenter comparison of a colorimetric microdilution broth method with the reference macrodilution method for in vitro susceptibility testing of yeast isolates.

Authors:  M A Pfaller; B Buschelman; M J Bale; M Lancaster; A Espinel-Ingroff; J H Rex; M G Rinaldi
Journal:  Diagn Microbiol Infect Dis       Date:  1994-05       Impact factor: 2.803

View more
  10 in total

1.  In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans.

Authors:  T Yamazumi; M A Pfaller; S A Messer; A Houston; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.

Authors:  M A Pfaller; J Zhang; S A Messer; M E Brandt; R A Hajjeh; C J Jessup; M Tumberland; E K Mbidde; M A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-t etrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents.

Authors:  S P Hawser; H Norris; C J Jessup; M A Ghannoum
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

4.  Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin.

Authors:  David van Duin; Arturo Casadevall; Joshua D Nosanchuk
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

5.  Fluconazole susceptibility testing of Cryptococcus neoformans: comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients.

Authors:  C J Jessup; M A Pfaller; S A Messer; J Zhang; M Tumberland; E K Mbidde; M A Ghannoum
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

6.  Correlation of fluconazole MICs with clinical outcome in cryptococcal infection.

Authors:  A I Aller; E Martin-Mazuelos; F Lozano; J Gomez-Mateos; L Steele-Moore; W J Holloway; M J Gutiérrez; F J Recio; A Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

7.  Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the E test.

Authors:  A E Simor; G Goswell; L Louie; M Lee; M Louie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-09       Impact factor: 3.267

8.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

Authors:  M E Brandt; M A Pfaller; R A Hajjeh; R J Hamill; P G Pappas; A L Reingold; D Rimland; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms.

Authors:  A Espinel-Ingroff; M Pfaller; S A Messer; C C Knapp; S Killian; H A Norris; M A Ghannoum
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans.

Authors:  T Yamazumi; M A Pfaller; S A Messer; A K Houston; L Boyken; R J Hollis; I Furuta; R N Jones
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.